{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T20:02:55Z","timestamp":1776283375729,"version":"3.50.1"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.bcp.2015.11.001","type":"journal-article","created":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T06:42:12Z","timestamp":1447137732000},"page":"73-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Basic chemokine-derived glycosaminoglycan binding peptides exert antiviral properties against dengue virus serotype 2, herpes simplex virus-1 and respiratory syncytial virus"],"prefix":"10.1016","volume":"100","author":[{"given":"Vincent","family":"Vanheule","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Vervaeke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anneleen","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Noppen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mieke","family":"Gouwy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Snoeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graciela","family":"Andrei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Liekens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Proost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2015.11.001_bib0005","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nrd2424","article-title":"The design of drugs for HIV and HCV","volume":"6","author":"De Clercq","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2015.11.001_bib0010","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev.biochem.78.082207.084029","article-title":"New antivirals and drug resistance","volume":"78","author":"Colman","year":"2009","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bcp.2015.11.001_bib0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.coviro.2012.12.002","article-title":"HIV-1 entry inhibitors: recent development and clinical use","volume":"3","author":"Henrich","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.bcp.2015.11.001_bib0020","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/infdis\/jit503","article-title":"Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study","volume":"209","author":"Sulkowski","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bcp.2015.11.001_bib0025","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.antiviral.2012.08.005","article-title":"Poly(4-styrenesulfonic acid-co-maleic acid) is an entry inhibitor against both HIV-1 and HSV infections\u2014potential as a dual functional microbicide","volume":"96","author":"Qiu","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.bcp.2015.11.001_bib0030","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0149-2918(08)80048-3","article-title":"Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection","volume":"30","author":"Lieberman-Blum","year":"2008","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bcp.2015.11.001_bib0035","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3389\/fimmu.2015.00277","article-title":"Maraviroc\u2014a CCR5 antagonist for the treatment of HIV-1 infection","volume":"6","author":"Van Der Ryst","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2015.11.001_bib0040","doi-asserted-by":"crossref","first-page":"e21658","DOI":"10.1371\/journal.pone.0021658","article-title":"Broad antiviral activity of carbohydrate-binding agents against the four serotypes of dengue virus in monocyte-derived dendritic cells","volume":"6","author":"Alen","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2015.11.001_bib0045","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.ajpath.2013.02.027","article-title":"Inflammatory and innate immune responses in dengue infection: protection versus disease induction","volume":"182","author":"Costa","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bcp.2015.11.001_bib0050","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/978-1-4899-2444-5_33","article-title":"Heparan sulfate glycosaminoglycans as primary cell surface receptors for herpes simplex virus","volume":"313","author":"Spear","year":"1992","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.bcp.2015.11.001_bib0055","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1083\/jcb.116.5.1273","article-title":"Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans","volume":"116","author":"Shieh","year":"1992","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bcp.2015.11.001_bib0060","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nm0897-866","article-title":"Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate","volume":"3","author":"Chen","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2015.11.001_bib0065","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1128\/JVI.72.2.1577-1585.1998","article-title":"A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate","volume":"72","author":"Chung","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2015.11.001_bib0070","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1006\/viro.1999.0171","article-title":"Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions","volume":"268","author":"Dechecchi","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.bcp.2015.11.001_bib0075","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1074\/jbc.M006701200","article-title":"Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans","volume":"276","author":"Tyagi","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2015.11.001_bib0080","first-page":"122","article-title":"Role of glycosaminoglycans for binding and infection of hepatitis B virus","volume":"10","author":"Leistner","year":"2008","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.bcp.2015.11.001_bib0085","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/628475","article-title":"Dengue virus entry as target for antiviral therapy","volume":"2012","author":"Alen","year":"2012","journal-title":"J. Trop. Med."},{"key":"10.1016\/j.bcp.2015.11.001_bib0090","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to inhibit entry of HBV and HDV into hepatocytes","volume":"147","author":"Urban","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2015.11.001_bib0095","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.3390\/molecules20022707","article-title":"Diversity of heparan sulfate and HSV entry: basic understanding and treatment strategies","volume":"20","author":"Tiwari","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2015.11.001_bib0100","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1747-0285.2008.00741.x","article-title":"The structure of glycosaminoglycans and their interactions with proteins","volume":"72","author":"Gandhi","year":"2008","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bcp.2015.11.001_bib0105","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1126\/science.271.5252.1116","article-title":"Heparin structure and interactions with basic fibroblast growth factor","volume":"271","author":"Faham","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.bcp.2015.11.001_bib0110","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3389\/fimmu.2015.00246","article-title":"Chemokines and glycosaminoglycans","volume":"6","author":"Proudfoot","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2015.11.001_bib0115","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1039\/b100916h","article-title":"Heparin and heparan sulfate: structure and function","volume":"19","author":"Rabenstein","year":"2002","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.bcp.2015.11.001_bib0120","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1937-6448(09)76003-4","article-title":"Interactions between heparan sulfate and proteins-design and functional implications","volume":"276","author":"Lindahl","year":"2009","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.bcp.2015.11.001_bib0125","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/joim.12061","article-title":"Pathophysiology of heparan sulphate: many diseases, few drugs","volume":"273","author":"Lindahl","year":"2013","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.bcp.2015.11.001_bib0130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0092-8674(00)80058-6","article-title":"A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry","volume":"99","author":"Shukla","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2015.11.001_bib0135","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/emboj\/20.1.19","article-title":"The fusion domain of HIV gp41 interacts specifically with heparan sulfate on the T-lymphocyte cell surface","volume":"20","author":"Cladera","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.bcp.2015.11.001_bib0140","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1172\/JCI200113799","article-title":"Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry","volume":"108","author":"Shukla","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2015.11.001_bib0145","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1128\/JVI.70.6.3461-3469.1996","article-title":"Differences in the susceptibility of herpes simplex virus types 1 and 2 to modified heparin compounds suggest serotype differences in viral entry","volume":"70","author":"Herold","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2015.11.001_bib0150","doi-asserted-by":"crossref","first-page":"24850","DOI":"10.1074\/jbc.272.40.24850","article-title":"Structural requirement of heparan sulfate for interaction with herpes simplex virus type 1 virions and isolated glycoprotein C","volume":"272","author":"Feyzi","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2015.11.001_bib0155","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.virol.2009.11.011","article-title":"Expanding the role of 3-O sulfated heparan sulfate in herpes simplex virus type-1 entry","volume":"397","author":"O\u2019Donnell","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.bcp.2015.11.001_bib0160","first-page":"385","article-title":"Suramin inhibits in vitro infection by duck hepatitis B virus, Rous sarcoma virus, and hepatitis delta virus","volume":"167","author":"Petcu","year":"1988","journal-title":"Virology"},{"key":"10.1016\/j.bcp.2015.11.001_bib0165","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/infdis\/jis273","article-title":"A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses","volume":"205","author":"Krepstakies","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bcp.2015.11.001_bib0170","doi-asserted-by":"crossref","first-page":"e0126239","DOI":"10.1371\/journal.pone.0126239","article-title":"Novel heparan sulfate-binding peptides for blocking herpesvirus entry","volume":"10","author":"Dogra","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2015.11.001_bib0175","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1146\/annurev.immunol.15.1.675","article-title":"Human chemokines: an update","volume":"15","author":"Baggiolini","year":"1997","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bcp.2015.11.001_bib0180","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0031-6997(24)01439-X","article-title":"International union of pharmacology. XXII. Nomenclature for chemokine receptors","volume":"52","author":"Murphy","year":"2000","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2015.11.001_bib0185","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood.V95.10.3032","article-title":"Chemokine receptors and their role in inflammation and infectious diseases","volume":"95","author":"Murdoch","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2015.11.001_bib0190","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1073\/pnas.0334864100","article-title":"Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines","volume":"100","author":"Proudfoot","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2015.11.001_bib0195","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1146\/annurev.immunol.22.012703.104543","article-title":"Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells","volume":"22","author":"Rot","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bcp.2015.11.001_bib0200","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev.biochem.72.121801.161747","article-title":"Regulation of protein function by glycosaminoglycans\u2014as exemplified by chemokines","volume":"74","author":"Handel","year":"2005","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bcp.2015.11.001_bib0205","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.cytogfr.2005.04.006","article-title":"Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention","volume":"16","author":"Johnson","year":"2005","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bcp.2015.11.001_bib0210","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.yexcr.2011.01.005","article-title":"Chemokines in health and disease","volume":"317","author":"Raman","year":"2011","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bcp.2015.11.001_bib0215","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.immuni.2012.05.008","article-title":"The chemokine superfamily revisited","volume":"36","author":"Zlotnik","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2015.11.001_bib0220","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M115.649855","article-title":"The positively charged COOH-terminal glycosaminoglycan binding CXCL9(74-103) peptide inhibits CXCL8-induced neutrophil extravasation and monosodium urate crystal-induced gout in mice","author":"Vanheule","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2015.11.001_bib0225","doi-asserted-by":"crossref","first-page":"e1110","DOI":"10.1371\/journal.pone.0001110","article-title":"The novel CXCL12gamma isoform encodes an unstructured cationic domain which regulates bioactivity and interaction with both glycosaminoglycans and CXCR4","volume":"2","author":"Laguri","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2015.11.001_bib0230","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/1523-1747.ep12613748","article-title":"HMEC-1: establishment of an immortalized human microvascular endothelial cell line","volume":"99","author":"Ades","year":"1992","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bcp.2015.11.001_bib0235","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0076-6879(09)05401-9","article-title":"Isolation, identification, and production of posttranslationally modified chemokines","volume":"461","author":"Loos","year":"2009","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.bcp.2015.11.001_bib0240","doi-asserted-by":"crossref","first-page":"10916","DOI":"10.18632\/oncotarget.2538","article-title":"Angiostatic, tumor inflammatory and anti-tumor effects of CXCL4(47-70) and CXCL4L1(47-70) in an EGF-dependent breast cancer model","volume":"5","author":"Van Raemdonck","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2015.11.001_bib0245","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1099\/0022-1317-81-3-639","article-title":"Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene","volume":"81","author":"Andrei","year":"2000","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.bcp.2015.11.001_bib0250","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1128\/AAC.49.11.4671-4680.2005","article-title":"Organotypic epithelial raft cultures as a model for evaluating compounds against alphaherpesviruses","volume":"49","author":"Andrei","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2015.11.001_bib0255","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1021\/jm00035a010","article-title":"Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues","volume":"37","author":"Sagi","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2015.11.001_bib0260","doi-asserted-by":"crossref","first-page":"e74035","DOI":"10.1371\/journal.pone.0074035","article-title":"Sulfated E. coli K5 polysaccharide derivatives inhibit dengue virus infection of human microvascular endothelial cells by interacting with the viral envelope protein E domain III","volume":"8","author":"Vervaeke","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2015.11.001_bib0265","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1084\/jem.184.3.963","article-title":"Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes","volume":"184","author":"Loetscher","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2015.11.001_bib0270","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.yexcr.2010.12.017","article-title":"CXCR3 in T cell function","volume":"317","author":"Groom","year":"2011","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bcp.2015.11.001_bib0275","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.cytogfr.2014.11.009","article-title":"CXCR3 ligands in disease and therapy","volume":"26","author":"Van Raemdonck","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bcp.2015.11.001_bib0280","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1081\/NCN-100002298","article-title":"Acyclic\/carbocyclic guanosine analogues as anti-herpesvirus agents","volume":"20","author":"De Clercq","year":"2001","journal-title":"Nucleosides Nucleotides Nucl. Acids"},{"key":"10.1016\/j.bcp.2015.11.001_bib0285","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1189\/jlb.0103024","article-title":"Many chemokines including CCL20\/MIP-3alpha display antimicrobial activity","volume":"74","author":"Yang","year":"2003","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.bcp.2015.11.001_bib0290","doi-asserted-by":"crossref","first-page":"623","DOI":"10.4049\/jimmunol.167.2.623","article-title":"Cutting edge: IFN-inducible ELR-CXC chemokines display defensin-like antimicrobial activity","volume":"167","author":"Cole","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2015.11.001_bib0295","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1128\/IAI.01208-08","article-title":"Antimicrobial effects of interferon-inducible CXC chemokines against Bacillus anthracis spores and bacilli","volume":"77","author":"Crawford","year":"2009","journal-title":"Infect. Immun."},{"key":"10.1016\/j.bcp.2015.11.001_bib0300","doi-asserted-by":"crossref","first-page":"29499","DOI":"10.1074\/jbc.M109.025957","article-title":"SufA of the opportunistic pathogen finegoldia magna modulates actions of the antibacterial chemokine MIG\/CXCL9, promoting bacterial survival during epithelial inflammation","volume":"284","author":"Karlsson","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2015.11.001_bib0305","doi-asserted-by":"crossref","first-page":"e58129","DOI":"10.1371\/journal.pone.0058129","article-title":"Human chemokines as antimicrobial peptides with direct parasiticidal effect on Leishmania mexicana in vitro","volume":"8","author":"Sobirk","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2015.11.001_bib0310","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1086\/510857","article-title":"The CXC chemokine MIG\/CXCL9 is important in innate immunity against Streptococcus pyogenes","volume":"195","author":"Egesten","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bcp.2015.11.001_bib0315","doi-asserted-by":"crossref","first-page":"e1004648","DOI":"10.1371\/journal.ppat.1004648","article-title":"CXCL9 contributes to antimicrobial protection of the gut during citrobacter rodentium infection independent of chemokine-receptor signaling","volume":"11","author":"Reid-Yu","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bcp.2015.11.001_bib0320","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1189\/jlb.1003524","article-title":"Synergistic induction of CXCL9 and CXCL11 by toll-like receptor ligands and interferon-gamma in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids","volume":"75","author":"Proost","year":"2004","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.bcp.2015.11.001_bib0325","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/labinvest.3700453","article-title":"TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis","volume":"86","author":"Loos","year":"2006","journal-title":"Lab. Invest."},{"key":"10.1016\/j.bcp.2015.11.001_bib0330","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1034\/j.1600-065X.2000.17720.x","article-title":"Interferon-inducible chemokines and immunity to poxvirus infections","volume":"177","author":"Mahalingam","year":"2000","journal-title":"Immunol. Rev."},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2015.11.001_bib0335","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1038\/sj.bjp.0707660","article-title":"Structure, function and physiological consequences of virally encoded chemokine seven transmembrane receptors","volume":"153","author":"Rosenkilde","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2015.11.001_bib0340","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1074\/jbc.M209470200","article-title":"Structure\u2013function relationship between the human chemokine receptor CXCR3 and its ligands","volume":"278","author":"Clark-Lewis","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2015.11.001_bib0345","doi-asserted-by":"crossref","first-page":"6991","DOI":"10.4049\/jimmunol.177.10.6991","article-title":"Oligomerization of CXCL10 is necessary for endothelial cell presentation and in vivo activity","volume":"177","author":"Campanella","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2015.11.001_bib0350","doi-asserted-by":"crossref","first-page":"17713","DOI":"10.1074\/jbc.M109.082552","article-title":"Characterization of the chemokine CXCL11-heparin interaction suggests two different affinities for glycosaminoglycans","volume":"285","author":"Severin","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2015.11.001_bib0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/med.1026","article-title":"Cell surface heparan sulfate and its roles in assisting viral infections","volume":"22","author":"Liu","year":"2002","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bcp.2015.11.001_bib0360","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.pharmthera.2009.05.001","article-title":"Sulfated K5 E. coli polysaccharide derivatives: a novel class of candidate antiviral microbicides","volume":"123","author":"Rusnati","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2015.11.001_bib0365","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1128\/JVI.70.6.3461-3469.1996","article-title":"Differences in the susceptibility of herpes simplex virus types 1 and 2 to modified heparin compounds suggest serotype differences in viral entry","volume":"70","author":"Herold","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2015.11.001_bib0370","doi-asserted-by":"crossref","first-page":"8206","DOI":"10.1128\/JVI.01302-15","article-title":"Global diversity within and between human herpesvirus 1 and 2 glycoproteins","volume":"89","author":"Lamers","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2015.11.001_bib0375","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.antiviral.2010.01.003","article-title":"Peptide-derivatized dendrimers inhibit human cytomegalovirus infection by blocking virus binding to cell surface heparan sulfate","volume":"85","author":"Luganini","year":"2010","journal-title":"Antivir. Res."},{"key":"10.1016\/j.bcp.2015.11.001_bib0380","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1128\/AAC.00471-10","article-title":"Identification of a dendrimeric heparan sulfate-binding peptide that inhibits infectivity of genital types of human papillomaviruses","volume":"54","author":"Donalisio","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2015.11.001_bib0385","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1128\/AAC.00149-11","article-title":"Inhibition of herpes simplex virus type 1 and type 2 infections by peptide-derivatized dendrimers","volume":"55","author":"Luganini","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2015.11.001_bib0390","doi-asserted-by":"crossref","first-page":"5278","DOI":"10.1128\/AAC.00771-12","article-title":"Inhibition of human respiratory syncytial virus infectivity by a dendrimeric heparan sulfate-binding peptide","volume":"56","author":"Donalisio","year":"2012","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295215007108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295215007108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T10:47:27Z","timestamp":1748688447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295215007108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":78,"alternative-id":["S0006295215007108"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2015.11.001","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Basic chemokine-derived glycosaminoglycan binding peptides exert antiviral properties against dengue virus serotype 2, herpes simplex virus-1 and respiratory syncytial virus","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2015.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}